Literature DB >> 11820911

Locally administered ocular corticosteroids: benefits and risks.

Charles N J McGhee1, Simon Dean, Helen Danesh-Meyer.   

Abstract

Corticosteroids, used prudently, are one of the most potent and effective modalities available in the treatment of ocular inflammation. However, they can produce a plethora of adverse ocular and systemic events. In order to optimise and target drug delivery, whilst minimising systemic adverse effects, a diverse range of local ophthalmic preparations and delivery techniques have been developed. Topical drops and ointments remain the primary methods for administration of ocular corticosteroids. However, ocular penetration of topical corticosteroid drops depends upon drug concentration, chemical formulation of corticosteroid, and composition of the vehicle, therefore, apparently small modifications in preparations can produce a more than 20-fold difference in intraocular drug concentration. Periocular injections of corticosteroids continue to have a useful, but limited, therapeutic role and longer acting, intraocular delayed-release devices are in early clinical studies. Although newer corticosteroids with lesser pressure elevating characteristics have been developed, corticosteroid-induced ocular hypertension and glaucoma continue to be significant risks of local and systemic administration. Posterior subcapsular cataract, observed following as little as 4 months topical corticosteroids use, is thought to be due to covalent binding of corticosteroid to lens protein with subsequent oxidation. Inappropriate use of topical corticosteroid in the presence of corneal infections also continues to be a cause of ocular morbidity. Other risks of locally administered ophthalmic corticosteroids include: tear-film instability, epithelial toxicity, crystalline keratopathy, decreased wound strength, orbital fat atrophy, ptosis, limitation of ocular movement, inadvertent intraocular injection, and reduction in endogenous cortisol. This extensive review assesses the therapeutic benefits of locally administered ocular corticosteroids in the context of the risks of adverse effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11820911     DOI: 10.2165/00002018-200225010-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  232 in total

1.  Orbital rim fat atrophy after repository periocular corticosteroid injection.

Authors:  R A Nozik
Journal:  Am J Ophthalmol       Date:  1976-12       Impact factor: 5.258

2.  CORTICOSTEROIDS AND INTRAOCULAR PRESSURE.

Authors:  B BECKER; D W MILLS
Journal:  Arch Ophthalmol       Date:  1963-10

3.  Corticosteroids in corneal graft rejection. Oral versus single pulse therapy.

Authors:  J C Hill; R Maske; P Watson
Journal:  Ophthalmology       Date:  1991-03       Impact factor: 12.079

4.  Steroid-induced cataract: new perspective from in vitro and lens culture studies.

Authors:  J E Dickerson; E Dotzel; A F Clark
Journal:  Exp Eye Res       Date:  1997-10       Impact factor: 3.467

5.  Corneal stromal calcification after topical steroid-phosphate therapy.

Authors:  U Schlötzer-Schrehardt; Z Zagórski; L M Holbach; C Hofmann-Rummelt; G O Naumann
Journal:  Arch Ophthalmol       Date:  1999-10

6.  Vitrectomy for accidental intraocular steroid injection.

Authors:  L Gopal; M Bhende; T Sharma
Journal:  Retina       Date:  1995       Impact factor: 4.256

7.  Use of orbital floor steroids in the management of patients with uniocular non-necrotising scleritis.

Authors:  K N Hakin; J Ham; S L Lightman
Journal:  Br J Ophthalmol       Date:  1991-06       Impact factor: 4.638

8.  Systemic dexamethasone concentration in horses after continued topical treatment with an ophthalmic preparation of dexamethasone.

Authors:  B M Spiess; S Nyikos; E Stummer; A Sahin; H Naegeli
Journal:  Am J Vet Res       Date:  1999-05       Impact factor: 1.156

9.  Liposomes in topical drug delivery.

Authors:  H E Schaeffer; D L Krohn
Journal:  Invest Ophthalmol Vis Sci       Date:  1982-02       Impact factor: 4.799

10.  Topically administered corticosteroids: effect on antibiotic-treated bacterial keratitis.

Authors:  H M Leibowitz; A Kupferman
Journal:  Arch Ophthalmol       Date:  1980-07
View more
  81 in total

1.  Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1.

Authors:  Naveen K Rajasagi; Pradeep B J Reddy; Amol Suryawanshi; Sachin Mulik; Per Gjorstrup; Barry T Rouse
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

Review 2.  Management of high-risk corneal transplantation.

Authors:  Antonio Di Zazzo; Ahmad Kheirkhah; Tulio B Abud; Sunali Goyal; Reza Dana
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

Review 3.  [Ocular involvement in spondyloarthropathies: HLA B27 associated uveitis].

Authors:  R Max; H M Lorenz; F Mackensen
Journal:  Z Rheumatol       Date:  2010-07       Impact factor: 1.372

4.  Corticosteroid eyedrops induced blepharoptosis and atrophy of levator muscle.

Authors:  Xiao Zhang; Mei-Fen Zhang; Da-Chun Zhao; Xiao-Wei Liu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-02-15       Impact factor: 3.117

Review 5.  Corneal nerves in health and disease.

Authors:  Brittany Simmons Shaheen; May Bakir; Sandeep Jain
Journal:  Surv Ophthalmol       Date:  2014-01-23       Impact factor: 6.048

6.  Soluble vascular endothelial growth factor receptor-3 suppresses allosensitization and promotes corneal allograft survival.

Authors:  Parisa Emami-Naeini; Thomas H Dohlman; Masahiro Omoto; Takaaki Hattori; Yihe Chen; Hyun Soo Lee; Sunil K Chauhan; Reza Dana
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-05       Impact factor: 3.117

7.  The artemisinin derivative artesunate inhibits corneal neovascularization by inducing ROS-dependent apoptosis in vascular endothelial cells.

Authors:  Rui Cheng; Cen Li; Chaoyang Li; Ling Wei; Lei Li; Yang Zhang; Yachao Yao; Xiaoqiong Gu; Weibin Cai; Zhonghan Yang; Jianxing Ma; Xia Yang; Guoquan Gao
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-05-15       Impact factor: 4.799

8.  Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution.

Authors:  Hyung Cho; Kenneth J Wolf; Eric J Wolf
Journal:  Clin Ophthalmol       Date:  2009-06-02

Review 9.  An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis.

Authors:  Susanna Esposito; Giulia Fior; Alessandro Mori; Silvia Osnaghi; Daniele Ghiglioni
Journal:  Paediatr Drugs       Date:  2016-10       Impact factor: 3.022

10.  A Prospective, Open-label Study to Compare the Efficacy and the Safety of Topical Loteprednol Etabonate and Topical Flurbiprofen Sodium in Patients with Post-Operative Inflammation after Cataract Extraction.

Authors:  Sheshidhar G Bannale; H P Pundarikaksha; H N Sowbhagya
Journal:  J Clin Diagn Res       Date:  2012-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.